Generic vs Brand Name Drugs: What Is the Same, What Differs and When It Matters
SafeRxPills Pharmacy Team
Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.

Generic Medicine vs Brand Medicine: Understanding the Differences - pharmacy guide
In this article (26 sections)
Generic and brand name drugs contain the same active ingredient at the same strength, in the same dosage form, taken the same way. What can differ is everything around that ingredient: the fillers and dyes, the shape and color of the tablet, the company name on the bottle, parts of the label and, most of all, the price. This page puts the two side by side, then covers the specific situations where the difference can matter for a patient (narrow therapeutic index drugs such as levothyroxine and warfarin, extended release tablets, inhalers and creams, ingredient allergies and switching between generic makers), and ends with a practical way to check what you were given.
Every number below comes from a source opened on 5 November 2026: FDA pages, the FDA Orange Book preface, the Code of Federal Regulations, PubMed abstracts and the 2026 savings report of the Association for Accessible Medicines. The sources are listed at the end. If you want the definition side of the topic (what a generic is, how the ANDA pathway and Hatch-Waxman work, and what an authorized generic is), read our companion guide what generic drugs are and how they are approved.
Generic vs brand name drugs: the short answer
The FDA says a generic must be the same as the brand in active ingredient, strength, dosage form and route of administration, must have the same label "with certain exceptions", and must be bioequivalent to the brand. The FDA Orange Book adds that products rated therapeutically equivalent "can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling."
For most people on most medicines, that is the whole story: a generic will work the same way. The cases where a switch deserves more attention are a short, known list, covered from the section on narrow therapeutic index drugs onward.
Side by side: what is the same and what can differ
| Feature | Brand name drug | FDA approved generic | Same or can differ? |
|---|---|---|---|
| Active ingredient | The original molecule | The same molecule | Same (required) |
| Strength | For example 100 mg | The same strength | Same (required) |
| Dosage form | Tablet, capsule, solution, cream, inhaler | The same dosage form | Same (required) |
| Route | By mouth, on the skin, inhaled, injected | The same route | Same (required) |
| Rate and extent of absorption | Reference values | Must be bioequivalent (90% confidence interval of the ratio within 80.00 to 125.00%) | Very close, not identical |
| Inactive ingredients | The brand's fillers, binders, dyes, preservatives | Can use different ones if they are safe | Can differ |
| Color, shape, size, scoring | The brand's trade dress | Usually different | Can differ |
| Release mechanism and packaging | The brand's design | Can differ while staying therapeutically equivalent | Can differ |
| Label | The approved brand label | The same label with permitted exceptions | Mostly same |
| Expiration date | Set by the brand maker | Set by the generic maker | Can differ |
| Manufacturing standards | FDA quality standards | The same FDA quality standards | Same |
| Price | Higher while it has no competition | Usually lower, falling as more makers enter | Differs |
The "can differ" rows come from the FDA Orange Book preface, which says therapeutically equivalent products "may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging", as well as excipients (including colors, flavors and preservatives), expiration date, certain aspects of labeling and storage conditions.
Active ingredient, strength, dosage form and route
These four are fixed. A generic of a 20 mg tablet taken by mouth has to be a 20 mg tablet taken by mouth that contains the same active ingredient. The Orange Book calls products that meet this test "pharmaceutical equivalents": "drug products in identical dosage forms and route(s) of administration" containing the same active ingredient in the same amount.
Being a pharmaceutical equivalent is not enough by itself. A tablet can contain the right amount of drug and still release it too slowly or too quickly. That is why the second test, bioequivalence, exists.
Bioequivalence: how close a generic has to be
The Orange Book defines bioequivalence as "the absence of a significant difference in the rate and extent to which the active ingredient" becomes available at the site of drug action. In practice, healthy volunteers take the generic and the brand in a crossover study, and blood levels are measured over time. Two numbers are compared: AUC (area under the blood level curve, the total amount absorbed) and Cmax (the peak level, a marker of how fast it is absorbed).
The FDA standard, as set out in an FDA Office of Generic Drugs presentation on narrow therapeutic index drugs, is that the "90% confidence interval (CI) for the geometric mean ratio of test/reference" must fall "within 80.00-125.00%". This is the most misread number in the whole topic.
| Common reading | What the rule says |
|---|---|
| A generic can contain 80% to 125% of the brand's dose | No. The strength on the label is the same. The 80 to 125% range applies to a statistical interval around the ratio of blood levels in a study. |
| A generic can be 20% weaker or 25% stronger | No. The whole 90% confidence interval must sit inside the range, so the average ratio has to be close to 100% for a study to pass. |
| Assay potency is the same thing | No. Potency of the tablet itself has its own limits: 90.0 to 110.0% for most drugs and 95.0 to 105.0% for narrow therapeutic index drugs, per the same FDA presentation. |
What the bioequivalence data show in practice
FDA scientists reviewed 2,070 single-dose bioequivalence studies behind oral generics approved from 1996 to 2007 (Davit and colleagues, 2009). The average generic to brand ratio was 1.00 for both measures (standard deviation 0.06 for Cmax and 0.04 for AUC).
| Measure | Average difference, generic vs brand |
|---|---|
| AUC (extent of absorption) | 3.56% |
| Cmax (peak level) | 4.35% |
| Studies where AUC differed by less than 10% | Nearly 98% |
Each study used between 12 and 170 subjects. The review's authors concluded that the FDA criteria support its aim of approving generics that are therapeutically equivalent to the brand. The data cover single-dose studies of orally administered generics only.
Inactive ingredients
Inactive ingredients (excipients) are the binders, fillers, coatings, dyes, flavors and preservatives that turn a powder into a usable tablet, liquid or cream. The generic maker can choose its own, and the Orange Book confirms that "preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products."
The FDA's Generic Drugs Q&A page (current as of 18 September 2026) answers the question of whether these differences matter: "In most cases no, but in a minority of patients, inactive ingredients may affect tolerability or absorption." It adds that the FDA will not approve a generic whose inactive ingredients are unsafe under the labeled conditions of use.
Why generics look different from the brand
A generic of a blue diamond tablet is rarely a blue diamond tablet. A 2003 FDA consumer brochure explains why: "trademark laws in the U.S. do not allow a generic drug to look exactly like other drugs already on the market." The same brochure notes that "generic drugs look different because certain inactive ingredients, such as colors and flavorings, may be different."
The current FDA Q&A puts it more briefly: "FDA generally allows minor differences in appearance between generic and brand drugs, such as in color," and "these minor differences do not affect how the medicine works." Appearance can still matter in a practical way. Older adults who sort pills by color, or anyone with several look-alike tablets, can mix them up after a refill brings a new color. If a refill looks different, check the label before assuming an error, and ask the pharmacist if it does not match.
Labeling: the same label with certain exceptions
The generic label has to match the brand's approved label. The regulation (21 CFR 314.94(a)(8)(iv)) lists the differences that are allowed. They "may include differences in expiration date, formulation, bioavailability, or pharmacokinetics", "labeling revisions made to comply with current FDA labeling guidelines or other guidance", and "omission of an indication or other aspect of labeling protected by patent or accorded exclusivity". Differences also follow from the products being made or distributed by different companies.
| Label item | What you might see on a generic |
|---|---|
| Manufacturer and distributor | The generic company, not the brand company |
| Inactive ingredient list | The generic's own excipients |
| Description and How Supplied | The generic's own color, shape and imprint |
| Indications | Occasionally one fewer use, when that use is still protected by a patent or exclusivity (a "carve-out") |
| Expiration date | Set by the generic's own stability data |
A carve-out does not mean the generic does not work for the missing use. It means the brand still holds legal protection for that wording. The warnings, dosing and contraindications for the uses that are listed stay the same.
Who makes brand name and generic drugs
A brand name drug is made or licensed by the company that developed it and holds the new drug application. Generics are made by companies that file an abbreviated application referring to that brand. An authorized generic, the brand's own product sold under its generic name, sits between the two. The approval route itself, and how authorized generics differ from ordinary generics, are covered in our generic drugs definition guide.
On manufacturing, the FDA's Q&A says: "Every batch of medication sold in the U.S. must meet the same strict quality standards," and "All approved drugs marketed in the U.S. must meet the same quality standards regardless of where they are made." The FDA Generic Drug Facts page adds that FDA conducts a pre-approval review, inspects manufacturing plants for compliance with good manufacturing practice rules, and monitors approved products.
Price: why generics cost less
The FDA's Generic Drug Facts page gives the reason: generic makers do not have to repeat the animal and human studies the brand needed, so their costs are lower. Prices then fall with competition. The same page says one generic competitor can lower prices by 30%, and five competitors are associated with price drops of nearly 85%.
| US, 2025 | Generics | Brand |
|---|---|---|
| Share of prescriptions filled | 89% | 11% |
| Share of prescription drug spending | 11.6% | 88.4% |
The Association for Accessible Medicines (the generic industry's trade group, working with the IQVIA Institute) reports that in 2025 generics "comprised 89% of all prescriptions filled, but only 11.6% of the total spent", while brand drugs made up "only 11% of prescriptions filled" and "88.4% of the total amount spent on prescription drugs". It puts the savings for patients and the US health system at $496 billion that year. For what US pharmacies actually pay for specific brand and generic products, see our brand vs generic drug prices guide using NADAC data.
Do generics work as well? What outcome studies show
Bioequivalence studies use healthy volunteers and blood levels. Outcome studies ask the patient question directly: do people on the generic do as well?
A systematic review in JAMA (Kesselheim and colleagues, 2008) pooled studies of cardiovascular generics published from 1984 to August 2008. It found 47 articles covering 9 drug classes, 38 of them randomized controlled trials.
| Drug class | Randomized trials reporting clinical equivalence |
|---|---|
| Beta-blockers | 7 of 7 |
| Diuretics | 10 of 11 |
| Calcium channel blockers | 5 of 7 |
| Antiplatelet agents | 3 of 3 |
| Statins | 2 of 2 |
| ACE inhibitors | 1 of 1 |
| Alpha-blockers | 1 of 1 |
| Warfarin (narrow therapeutic index) | 5 of 5 |
| Class 1 antiarrhythmics (narrow therapeutic index) | 1 of 1 |
The pooled effect size across 837 patients was -0.03 (95% CI -0.15 to 0.08), "indicating no evidence of superiority of brand-name to generic drugs." The same review found that 23 of 43 editorials (53%) took a negative view of generic substitution, which shows how far opinion had run ahead of the evidence.
A larger US claims study (Desai and colleagues, PLoS Medicine 2019) compared outcomes for eight products across 2,264,774 matched pairs of patients on authorized generics and ordinary generics. In 12 of 16 comparisons the outcomes were similar; of the other 4, 3 favored the generic and 1 favored the authorized generic. Where generic users of sertraline and escitalopram had slightly more psychiatric hospital stays than brand users, a matching gap appeared between authorized generic and brand users, which the authors said was likely explained by residual confounding or by negative perceptions of generics rather than by the tablets.
When the difference between generic and brand can matter
The evidence above supports generic substitution for the large majority of drugs. A short list of situations deserves more care, either because small changes in blood level matter more, because the product is harder to copy exactly, or because of the patient rather than the drug.
| Situation | Why it gets attention | Sensible step |
|---|---|---|
| Narrow therapeutic index drugs (warfarin, levothyroxine, phenytoin, tacrolimus and others) | Small changes in blood level can matter | Keep monitoring as prescribed, especially after any switch |
| Antiseizure medicines | Patient and doctor concern about breakthrough seizures | Talk to the prescriber before switching; monitor high-risk patients |
| Extended release tablets | Release mechanism can differ between makers | Report any change in effect or side effects after a switch |
| Inhalers, creams, eye drops, injections | Device or vehicle matters, not only the drug | Ask the pharmacist to show the new device; check the TE code |
| Excipient allergy or intolerance (dyes, lactose, gluten and others) | Inactive ingredients differ between makers | Read the inactive ingredient list on each new maker's label |
| Frequent changes between generic makers | Each refill can bring a different product | Ask the pharmacy whether it can keep you on the same maker |
Narrow therapeutic index drugs
An FDA CDER interview on narrow therapeutic index (NTI) drugs describes them as "a small set of drugs" that "have a much tighter therapeutic window", naming "the anticoagulant warfarin and the synthetic thyroid hormone levothyroxine" as examples. In an FDA Office of Generic Drugs presentation comparing regulators, FDA's examples are warfarin, tacrolimus, sirolimus, phenytoin, carbamazepine and levothyroxine; Health Canada's list also includes digoxin, flecainide, lithium, cyclosporine and theophylline. The presentation's slide on how FDA determines NTI status marks carbamazepine, phenytoin, valproic acid and tacrolimus as NTI, and lamotrigine, levetiracetam and topiramate as not NTI.
The FDA does not leave the standard 80 to 125% test alone for these drugs. Per the same presentation, a generic NTI drug:
- must pass a reference-scaled limit set from the brand's within-subject variability (narrower when the brand is less variable), and also the unscaled 80.00 to 125.00% limits;
- must show that the upper limit of the 90% confidence interval for the ratio of within-subject standard deviations is 2.5 or less, so the generic is not more variable than the brand;
- must meet assay potency of 95.0 to 105.0%, instead of 90.0 to 110.0% for other drugs.
The FDA's position, in the CDER interview, is that "generic NTI drugs, like all generic drugs, are FDA-approved as clinically substitutable with their brand-name versions," and that FDA "applies tighter quality and BE criteria for generic NTI drugs than for generic non-NTI drugs." In the pharmacist survey cited in the FDA presentation, 82% almost always substituted a generic NTI drug on a first prescription, but only 60% did so on refills.
Levothyroxine and switching between generic makers
Levothyroxine is the drug patients most often ask about. The worry is less about brand versus generic than about generic A versus generic B, because a pharmacy can change suppliers between refills. An FDA-sponsored study in JAMA Internal Medicine (Brito and colleagues, 2022) looked at this directly using US claims data linked to lab results for adults on a stable generic dose with a normal TSH.
| Result 6 weeks to 12 months later (2,780 matched pairs) | Stayed on same maker | Switched maker |
|---|---|---|
| Normal TSH (0.3 to 4.4 mIU/L) | 82.7% | 84.5% |
| Markedly abnormal TSH (below 0.1 or above 10.0 mIU/L) | 3.1% | 2.5% |
| Mean TSH | 2.7 mIU/L | 2.7 mIU/L |
Of 15,829 patients, 17.6% switched. Neither difference was statistically significant (P = .07 for normal TSH, P = .14 for markedly abnormal). The authors note that their finding conflicts with guideline advice warning about switching, and the FDA summary of the study says it "was not designed to assess the therapeutic equivalence of levothyroxine products." A fair reading: switching was not linked to a measurable change in thyroid tests for most stable adults, and checking TSH after a change remains reasonable, and the results do not apply to pregnancy, which the study excluded.
Antiseizure medicines
Epilepsy is where anecdotes about generics are strongest. A 2010 meta-analysis (Kesselheim and colleagues, Drugs) found 16 studies. Seven randomized trials could be pooled (204 patients): the odds ratio for uncontrolled seizures on generic versus brand was 1.1 (95% CI 0.9 to 1.2), meaning no difference. Observational studies did show changes in drug and health service use after switches, which the authors suggested might reflect concern from patients or doctors after a recent switch.
The authors also wrote that "physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs." That is the practical message: generics of these drugs are not shown to be worse, but a switch in someone whose seizures are hard to control is a reason to plan monitoring with the prescriber.
Extended release tablets: the bupropion XL 300 mg case
Modified release products are harder to copy because the release mechanism, not just the drug, decides the blood level over the day. The Orange Book lists release mechanism among the features that can differ between equivalent products.
The best known failure is Budeprion XL 300 mg (made by Impax, sold by Teva). In an FDA update dated 3 October 2012, an FDA-sponsored study in 24 healthy adults found the tablets "fail to release bupropion into the blood at the same rate and to the same extent as Wellbutrin XL 300 mg." FDA changed its Orange Book code from AB to BX, Impax asked FDA to withdraw approval of the 300 mg tablets, and the companies stopped shipping it. FDA asked the other makers of 300 mg generics for their own studies. The case cuts both ways: one generic did not match, and post-marketing checks caught it.
Inhalers, creams and other complex products
For an inhaler, the device is part of the medicine: how hard you need to breathe in, how the counter works and how the dose is loaded all affect what reaches the lungs. For a cream, eye drop or patch, the vehicle and the way the product spreads or sticks can matter. In the Orange Book, rated generic metered dose and dry powder inhalers are generally coded AB, and so are creams supported by in vivo bioequivalence data. AN is used for solutions and powders for aerosolization in general-use delivery systems such as nebulizers, and AT for topical solutions and certain topical products granted a waiver of in vivo bioequivalence testing.
If a pharmacy switches your inhaler to a generic with a different device, ask the pharmacist to show you how to use it before you rely on it. Our guide to generic Advair and Seroflo strengths shows how inhaler strength labels can differ between products.
Excipient allergies and intolerances
Because inactive ingredients can change from one maker to another, a person who reacts to a specific dye, lactose, gluten, a preservative or another excipient may tolerate one version and not the next. This is the "minority of patients" the FDA Q&A refers to.
Each US label lists the inactive ingredients in the Description section. If you have a known excipient allergy, read that list on every new supplier's label, tell the pharmacist, and ask your prescriber to note it on the prescription.
Who decides whether you get the generic
The FDA rates products; it does not decide what your pharmacist hands over. The Orange Book preface notes that "generic substitution may involve social and economic policy administered by the states," and that state laws vary, some limiting substitution to drugs on a specific list. What your pharmacist may substitute, and when the prescriber's instructions override it, depends on your state and your insurance plan.
If you or your doctor want the brand, say so before the prescription is filled. Ask how the cost changes under your plan before you decide.
How to tell what you were given: Orange Book TE codes
The FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) gives each multisource product a therapeutic equivalence (TE) code. The first letter tells you most of what you need.
| Code | Meaning (Orange Book preface) |
|---|---|
| A (any A code) | FDA considers the product therapeutically equivalent to other pharmaceutically equivalent products |
| AA | Conventional dosage forms without bioequivalence problems |
| AB, AB1, AB2... | Meets the necessary bioequivalence requirements. A number is added when more than one reference product of the same strength is listed, and products are equivalent only to others with the same three-character code |
| AN | Solutions and powders for aerosolization used in general-use delivery systems (such as nebulizers). Rated generic metered dose and dry powder inhalers are generally AB, not AN |
| AO | Injectable oil solutions (same active ingredient, concentration and oil) |
| AP | Injectable aqueous solutions |
| AT | Topical solutions and certain topical products granted a waiver of in vivo bioequivalence testing. Creams supported by in vivo bioequivalence data are AB |
| B (any B code) | Not considered therapeutically equivalent at this time; bioequivalence issues not resolved |
| BX | Data insufficient to determine therapeutic equivalence; presumed not equivalent until FDA decides otherwise |
To check a product: search the Orange Book by active ingredient, find your strength and dosage form, and look at the TE code next to the manufacturer on your bottle. An AB-rated generic of an AB-rated reference product is what most pharmacies substitute. With AB1 and AB2 codes, products are equivalent only within the same code; the Orange Book's own example is Adalat CC (AB1) and Procardia XL (AB2), which "are not bioequivalent to each other."
Checking a pill: label, imprint, DailyMed and the pharmacist
- Read the bottle label. US pharmacy labels name the drug and strength and often the manufacturer. The manufacturer name is what you look up.
- Check the imprint. Tablets and capsules usually carry an imprint code of letters or numbers. The label's How Supplied section on DailyMed describes the color, shape and imprint of each strength, so you can match the pill in your hand to a specific maker.
- Read the inactive ingredients. The same DailyMed label lists them in the Description section.
- Look up the TE code in the Orange Book, as above.
- Ask the pharmacist. They can tell you the maker, whether it changed since your last fill, and whether they can order a specific maker for you.
- Report problems. If you notice a change in effect or new side effects after a switch, tell your prescriber. Patients and clinicians can report to FDA MedWatch.
Authorized generics and branded generics, briefly
An authorized generic is the brand product sold under its generic name. The Desai study describes these as "identical in composition and appearance to brand-name products but are marketed as generics." If you want the brand formula at a generic price, ask whether an authorized generic exists. More on these in our guide to what generic drugs are.
A branded generic is a generic sold under its own trade name, which is common in India and many other countries. That is a separate topic; see our generic vs branded generics guide. Older background on the same question is in are generic drugs really the same.
A worked example: generic sildenafil
Sildenafil, the active ingredient in Viagra, is a useful example because many US generics exist and they look nothing like the brand's blue tablet. The approval logic is the same as for any oral tablet: same molecule, same strength, bioequivalent blood levels. What the bioequivalence studies show for sildenafil specifically is covered in does generic Viagra work as well as Viagra, and who makes US generics in generic Viagra in the US.
Where SafeRxPills fits
SafeRxPills sells generic medicines made by Indian manufacturers. These are not US FDA-approved generics: they were not approved through an ANDA, they have no Orange Book TE code, and nothing on this page about FDA bioequivalence standards applies to them. The FDA says "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use", and describes limited situations in which it may use enforcement discretion, on its personal importation page. Check your own situation with that page and your prescriber before ordering.
| Product | Active ingredient and strength | Maker | Pack price, 5 November 2026 | Per tablet |
|---|---|---|---|---|
| Cenforce 100 mg | Sildenafil citrate 100 mg | Centurion Laboratories | $83.00 for 90 tablets | $0.92 |
| Vidalista 20 mg | Tadalafil 20 mg | Centurion Laboratories | $84.00 for 90 tablets | $0.93 |
Before buying any medicine online, read our checklist on how to verify an online pharmacy.
Bottom line
Generic and brand name drugs share the parts that do the work: active ingredient, strength, form and route, with absorption held within tight statistical limits and, in FDA's review of 2,070 studies, an average difference of 3.56% to 4.35%. Outcome studies in heart disease, warfarin, epilepsy and thyroid disease have not shown the brand to be better. The differences that do exist (inactive ingredients, look, device design, release mechanism and frequent changes of maker) are worth knowing about for narrow therapeutic index drugs, extended release tablets, inhalers and excipient allergies. In those cases, keep up monitoring after any switch and use the Orange Book, DailyMed and your pharmacist to check exactly what you have.
Sources
- FDA. Generic Drug Facts. Content current as of 1 November 2021. fda.gov
- FDA. Generic Drugs: Questions and Answers. Content current as of 18 September 2026. fda.gov
- FDA. Orange Book Preface, 46th edition. Content current as of 15 January 2026. fda.gov
- FDA. Generic Drugs: Safe. Effective. FDA Approved. DHHS Publication No. (FDA) 02-3243 (2003). fda.gov
- 21 CFR 314.94(a)(8)(iv). ecfr.gov
- FDA CDER. Setting and Implementing Standards for Narrow Therapeutic Index Drugs. Content current as of 26 February 2024. fda.gov
- FDA Drug Topics: Understanding Generic Narrow Therapeutic Index Drugs (Jiang W, Office of Generic Drugs). fda.gov
- FDA. A Real-World Case Study of Levothyroxine Use. Content current as of 5 May 2022. fda.gov
- FDA. Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies, 3 October 2012. fda.gov
- FDA. Personal Importation. Content current as of 18 August 2025. fda.gov
- Davit BM et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009. PMID 19776300.
- Kesselheim AS et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008. PMID 19050195.
- Kesselheim AS et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010. PMID 20329806.
- Desai RJ et al. Comparative effectiveness of generic and brand-name medication use: a database study of US health insurance claims. PLoS Med 2019. PMID 30865626.
- Brito JP et al. Association between generic-to-generic levothyroxine switching and thyrotropin levels among US adults. JAMA Intern Med 2022. PMID 35226058.
- Association for Accessible Medicines. 2026 U.S. Generic and Biosimilar Medicines Savings Report. accessiblemeds.org
Related Topics:
?Frequently Asked Questions
What is the difference between generic and brand name drugs?
An FDA approved generic has the same active ingredient, strength, dosage form and route as the brand and must be bioequivalent to it. What can differ is the inactive ingredients, color, shape and size, the release mechanism and packaging, the expiration date, parts of the label such as the manufacturer name, and the price.
Are generic drugs as effective as brand name drugs?
For FDA approved generics, the evidence says yes for most drugs. A 2008 JAMA meta-analysis of cardiovascular generics found no evidence that the brand was better (pooled effect size -0.03 across 837 patients), and a 2010 meta-analysis of antiseizure drugs found no difference in uncontrolled seizures (odds ratio 1.1).
Can a generic contain 80% to 125% of the brand's dose?
No. The strength is the same. The 80.00 to 125.00% range is the limit for the 90% confidence interval of the ratio of blood levels in a bioequivalence study. In FDA's review of 2,070 such studies, the average difference from the brand was 3.56% for AUC and 4.35% for Cmax.
Why does my generic look different from the brand?
A 2003 FDA brochure says trademark laws in the US do not allow a generic drug to look exactly like other drugs already on the market, and that colors and flavorings may differ. The current FDA Q&A says these minor differences in appearance do not affect how the medicine works.
Can inactive ingredients in a generic cause problems?
The FDA answer is: in most cases no, but in a minority of patients, inactive ingredients may affect tolerability or absorption. If you have an allergy to a dye, lactose or another excipient, read the inactive ingredient list on each new maker's label and tell your pharmacist.
Which drugs need extra care when switching from brand to generic?
Narrow therapeutic index drugs, for which FDA's examples include warfarin, levothyroxine, tacrolimus, sirolimus, phenytoin and carbamazepine; antiseizure medicines in people with hard to control seizures; extended release tablets; and inhalers or other products where the device matters. FDA applies tighter standards to NTI generics, and monitoring after any switch is sensible.
Is it safe to switch between different generic levothyroxine makers?
An FDA-sponsored study of 2,780 matched pairs of US adults on stable doses found normal TSH in 84.5% of those who switched makers and 82.7% of those who did not, with mean TSH of 2.7 mIU/L in both groups. Pregnant patients were excluded. Your doctor may still check TSH after a change.
How can I tell if my generic is rated equivalent to the brand?
Look up the active ingredient in the FDA Orange Book and find the therapeutic equivalence code next to your manufacturer. Codes beginning with A, such as AB, mean FDA considers the product therapeutically equivalent. Codes beginning with B, such as BX, mean it is not rated equivalent.
Has a generic ever been found not equivalent to its brand?
Yes. In 2012 an FDA-sponsored study found Budeprion XL 300 mg did not release bupropion into the blood at the same rate and to the same extent as Wellbutrin XL 300 mg. FDA changed its rating from AB to BX, the maker asked FDA to withdraw approval of the 300 mg tablets, and shipping stopped.
Why are generic drugs cheaper than brand name drugs?
Generic makers do not repeat the brand's animal and human studies, and prices fall as competitors enter. The FDA says one generic competitor can lower prices by 30% and five are associated with drops of nearly 85%. In 2025, generics were 89% of US prescriptions filled but 11.6% of spending, and brands 11% and 88.4%, per the AAM.
Are the generics sold by SafeRxPills FDA approved?
No. SafeRxPills sells generics made by Indian manufacturers. They are not FDA approved generics, have no Orange Book equivalence code, and the FDA says that in most circumstances it is illegal for individuals to import drugs into the US for personal use. Check the FDA personal importation page and your own situation first.
SafeRxPills Pharmacy Team
SafeRxPills Editorial Team
Editorial team at SafeRxPills. Articles are written and checked against regulatory drug labelling (DailyMed, FDA, EMA) and published literature.
Comments (0)
Leave a Comment
No comments yet. Be the first to share your thoughts!
Related Articles

What Are Generic Drugs? Generic Name vs Brand Name, FDA Approval, Patents and the Orange Book
June 15, 2026


Brand vs Generic Drug Prices: What US Pharmacies Pay for Viagra, Cialis, Latisse and More (NADAC, October 2026)
October 19, 2026
